IMVARIA's Bronchosolve Solution Demonstrates Significant Breakthrough in Lung Cancer Diagnosis

Strategic Insights -

Researchers at IMVARIA Inc. have achieved a major technological advancement in the development of a fully-automated Bronchosolve solution, designed to diagnose lung cancer non-invasively through the assessment of suspicious pulmonary nodules. The platform, which has been tested in the pivotal VIRTUAL-BRONCH Study, has demonstrated improved accuracy relative to standard clinical assessments, with top-line results showing increased correct cancer classification independently and in combination with expert radiologists and pulmonologists.

Key Takeaways:

  • The Bronchosolve solution, developed by IMVARIA Inc., is a fully-automated, end-to-end platform that streamlines the workflow for clinicians, eliminating the need for manual data and imaging manipulation.
  • The pivotal VIRTUAL-BRONCH study analyzed cases from patients from multiple major cancer centers and health systems in the U.S., with the objective of assessing Bronchosolve's ability to diagnose lung cancer non-invasively through an efficient workflow, in both screening and non-screening cases with suspicious pulmonary nodules.
  • The primary endpoints of the study were met, demonstrating improved accuracy relative to standard clinical assessments.
  • The platform is designed to advance a more accurate, non-invasive way to identify lung cancer through cutting-edge AI capabilities uniquely built by medical doctors.
  • IMVARIA's Fibresolve diagnostic service for pulmonary fibrosis has been successful in over 30 medical institutions around the U.S.

Statistics:

  • Every two minutes, someone in the U.S. is diagnosed with lung cancer, and every day, lung cancer takes the lives of more than 360 people, according to the American Lung Association.
  • Lung cancer is the leading cause of cancer death worldwide, accounting for 19% of all cancer deaths, according to the American Cancer Society.
  • The chance that a man will develop lung cancer in his lifetime is about 1 in 17, and for a woman, the risk is about 1 in 18, according to the American Cancer Society.

Sources:

  • Business Wire
  • American Lung Association
  • American Cancer Society
  • IMVARIA Inc. press release.